An artificial intelligence (AI)-designed vaccine, developed by a research team from Cambridge University and Southampton University, has successfully completed its first phase of human trials. This marks a significant step in the quest for a universal vaccine.

This candidate vaccine represents a groundbreaking achievement: it is the first time an active vaccine component designed entirely through computer simulation has entered human trials, according to the research team.

The technology's distinction lies in its innovative antigen creation. Rather than targeting individual circulating virus strains with constant updates, the scientific team leveraged AI. They analyzed gene sequence data from all recorded sarbecoviruses to design a "super-antigen" that incorporates the most common, stable characteristics of the entire virus family. This 'universal vaccine' aims to protect against various sarbecoviruses, including SARS-CoV-2, which caused the Covid-19 pandemic, and other related viruses with zoonotic potential. The findings were published in the Journal of Infection.

Vial of the AI-designed vaccine. Illustration generated by AI.

Furthermore, the vaccine's delivery method is also novel. It is administered using high-pressure micro-jet technology applied transdermally, bypassing traditional needles. This approach could accelerate widespread vaccination efforts and reduce psychological barriers for individuals with needle phobias.

During the initial phase one trial, 39 healthy volunteers participated. The primary objectives were to assess the vaccine's safety and its ability to generate an immune response. Initial results confirmed the vaccine was safe, well-tolerated, and successfully activated an immune response.

This proactive approach is expected to enable the vaccine to not only address existing variants but also maintain efficacy against related viruses not yet seen in humans. Researchers aim to create a more robust prevention platform for future outbreaks, moving beyond merely reacting to viral mutations.

However, scientists emphasize this is a preliminary step. The initial trial primarily assessed safety and is insufficient to confirm real-world protective efficacy. Subsequent research phases will require expansion to a larger scale, involving a more diverse participant group to determine the vaccine's broad and sustained protection.

Given the continuous emergence of new pathogens, these results are a positive signal for applying AI in vaccine development. If proven effective in subsequent phases, this "pre-emptive disease" design model could pave the way for new preparedness strategies against future global health threats.

Van Ha (According to BBC, Fox News)